Literature DB >> 16678556

Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders.

Michael Camilleri1, Lionel Bueno, Fabrizio de Ponti, Jean Fioramonti, R Bruce Lydiard, Jan Tack.   

Abstract

Medications are commonly used for the treatment of patients with functional gastrointestinal disorders. The general goal of this report is to review the pharmacokinetics and pharmacology of medications used in functional gastrointestinal disorders. Methods included literature review, consensus evaluation of the evidence for each topic assigned originally to 1 or 2 authors, and broader review at a harmonization session as part of the Rome III process. This report reviews the animal models that have been validated for the study of effects of pharmacologic agents on sensation and motility; the preclinical pharmacology, pharmacokinetics, and toxicology usually required for introduction of novel therapeutic agents; the biomarkers validated for studies of sensation and motility end points with experimental medications in humans; the pharmacogenomics applied to these medications and disorders; and the pharmacology of agents that are applied or have potential for treatment of functional gastrointestinal disorders, including psychopharmacologic agents. Clinician and basic investigators involved in the treatment or investigation of functional gastrointestinal disorders or disease models need to have a comprehensive understanding of a vast range of medications. It is anticipated that the interaction between investigators of basic science, basic and applied pharmacology, and clinical trials will lead to better treatment of these disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16678556     DOI: 10.1053/j.gastro.2005.08.062

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

1.  Vagotomy upregulates expression of the N-methyl-D-aspartate receptor NR2D subunit in the stomach.

Authors:  Kanako Watanabe; Takeshi Kanno; Tadayuki Oshima; Hiroto Miwa; Chikara Tashiro; Tomoyuki Nishizaki
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

2.  All Roads Lead to Rome: Update on Rome III Criteria and New Treatment Options.

Authors:  David Q Shih; Lola Y Kwan
Journal:  Gastroenterol Rep       Date:  2007       Impact factor: 3.651

Review 3.  The enteric nervous system and neurogastroenterology.

Authors:  John B Furness
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-03-06       Impact factor: 46.802

4.  Improved health-related quality of life after surgical management of severe refractory constipation-dominant irritable bowel syndrome.

Authors:  Jennifer Y Lam; Biniam Kidane; Farouq Manji; Brian M Taylor
Journal:  Int Surg       Date:  2015-01

Review 5.  The role of experimental models in developing new treatments for irritable bowel syndrome.

Authors:  Daniel P Holschneider; Sylvie Bradesi; Emeran A Mayer
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 3.869

Review 6.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

7.  Biopsychosocial model of irritable bowel syndrome.

Authors:  Yukari Tanaka; Motoyori Kanazawa; Shin Fukudo; Douglas A Drossman
Journal:  J Neurogastroenterol Motil       Date:  2011-04-27       Impact factor: 4.924

8.  Psychopharmacological treatment and psychological interventions in irritable bowel syndrome.

Authors:  Emanuele Sinagra; Claudia Romano; Mario Cottone
Journal:  Gastroenterol Res Pract       Date:  2012-08-22       Impact factor: 2.260

9.  Ehlers-danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations.

Authors:  Marco Castori
Journal:  ISRN Dermatol       Date:  2012-11-22

10.  Drug development for the irritable bowel syndrome: current challenges and future perspectives.

Authors:  Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.